MAZE - CIK 0001842295
The table below shows Maze Therapeutics, Inc.'s income statement line items across its last 2 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | - | $167.50M |
| Cost of revenue | - | - |
| Gross profit | - | - |
| R&D | $108.45M | $83.50M |
| SG&A | $34.45M | $26.42M |
| Operating income | -$142.90M | $57.59M |
| Income tax | $0.00 | $1.17M |
| Net income | -$131.12M | $52.23M |
| EPS (diluted) | -$3.05 | $1.25 |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.